LNP1892

LNP1892 is a novel, orally available small molecule developed as a precision calcimimetic for the treatment of hyperparathyroidism, particularly secondary hyperparathyroidism associated with chronic kidney disease. It acts as a positive allosteric modulator of the calcium-sensing receptor (CaSR), thereby increasing the sensitivity of CaSR to extracellular calcium and reducing parathyroid hormone (PTH) secretion. LNP1892 was designed through systematic optimization of cinacalcet to improve pharmacokinetic properties and reduce side effects such as hypocalcemia. Preclinical studies demonstrated robust efficacy in lowering PTH levels in animal models without causing symptomatic hypocalcemia. Phase 1 clinical trials confirmed its safety and effectiveness in healthy volunteers, but development for hyperparathyroidism was discontinued after Phase 2 trials by Lupin[1][2][3][4].